Hartford Funds Management Co LLC Acquires 95 Shares of Zoetis Inc. (NYSE:ZTS)

Hartford Funds Management Co LLC boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 4.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,130 shares of the company’s stock after acquiring an additional 95 shares during the quarter. Hartford Funds Management Co LLC’s holdings in Zoetis were worth $416,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Mizuho Securities USA LLC raised its stake in Zoetis by 13,726.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock valued at $950,524,000 after buying an additional 4,829,815 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Zoetis by 4.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,687,902 shares of the company’s stock valued at $812,695,000 after buying an additional 178,303 shares during the last quarter. Clearbridge Investments LLC raised its stake in Zoetis by 5.8% during the 2nd quarter. Clearbridge Investments LLC now owns 3,044,384 shares of the company’s stock valued at $527,774,000 after buying an additional 166,517 shares during the last quarter. Principal Financial Group Inc. raised its stake in Zoetis by 17.3% during the 3rd quarter. Principal Financial Group Inc. now owns 2,377,403 shares of the company’s stock valued at $464,497,000 after buying an additional 351,372 shares during the last quarter. Finally, Sarasin & Partners LLP raised its stake in Zoetis by 546.3% during the 2nd quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock valued at $390,682,000 after buying an additional 1,904,899 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Trading Up 0.1 %

Shares of ZTS stock opened at $176.96 on Friday. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The firm has a market capitalization of $79.84 billion, a PE ratio of 33.26, a PEG ratio of 2.71 and a beta of 0.90. The stock has a fifty day simple moving average of $185.62 and a two-hundred day simple moving average of $180.61.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the prior year, the business posted $1.36 EPS. Zoetis’s revenue for the quarter was up 11.6% compared to the same quarter last year. On average, analysts predict that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be paid a $0.432 dividend. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.98%. Zoetis’s payout ratio is presently 32.52%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. JPMorgan Chase & Co. boosted their target price on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Stifel Nicolaus boosted their target price on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. BTIG Research upped their price objective on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Piper Sandler upped their price objective on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and an average price target of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.